Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020

Abstract

Purpose

Endocrinology and Metabolism Research Institute (EMRI), Tehran University of Medical Sciences, has achieved many advances in the understanding of epidemiology, pathology, and molecular biology of thyroid cancer (TC). This paper will focus on published literature in the field of TC research at EMRI since its inception.

Methods

A comprehensive literature search of “Scopus”, “Web of Science (ISI)”, “PubMed”, and “SID” databases was done to identify TC-based studies in EMRI since 2005, using the predefined keywords.

Results

All the records were reviewed. Eventually, 46 articles that met the inclusion and exclusion criteria were considered. Timeline, characteristics, and summarized findings of the included most studies have been briefly described.

Conclusion

The main focus of the TC research at EMRI is to investigate genetic and epigenetic changes as well as the cellular and molecular aspects seen more frequently in TC patients, and find out how exactly these alterations lead to more aggressive TC behavior and resistance to the conventional treatment approaches in those patients.

This is a preview of subscription content, access via your institution.

Abbreviations

1H-NMR:

hydrogen-1 nuclear magnetic resonance

3D:

three-dimensional

ABC:

ATP binding cassette

AGREE:

Appraisal of Guidelines Research and Evaluation

ATC:

anaplastic thyroid carcinoma

BRAF:

v-Raf murine sarcoma viral oncogene homolog B

CASC2:

cancer susceptibility candidate 2

CDH1:

cadherin 1

cfDNA:

circulating cell-free DNA

CFSE:

5,6-carboxyfluorescein N-hydroxysuccinimidyl ester

CSC:

cancer stem cell

ctDNA:

circulating tumor DNA

Ci:

cuire

DAPK:

death associated protein kinase

DNMT1:

DNA methyltransferase 1

DTC:

differentiated thyroid cancer

EGFRvIII:

epithelial growth factor receptor variant III

EMRI:

endocrinology and metabolism research institute

FSCN1:

fascin actin-bundling protein 1

FTA:

follicular thyroid adenoma

FTC:

follicular thyroid carcinoma

GAS5:

growth arrest special 5

GBq:

gigabecquerel

GM:

gut microbiome

HLA-C:

major histocompatibility complex class I C

HLA-DR:

major histocompatibility complex class II DR

HLA-DRB1:

major histocompatibility complex class II DR beta1

HOTAIRM1:

HOX antisense intergenic RNA myeloid 1

IHC:

immunohistochemical

I :

iodine

LncRNA:

long non-coding RNA

IRMA:

immunoradiometric assay

Klhl14:

kelch like family member 14

MACS:

magnetic-activated cell sorting

MALAT1:

metastasis associated lung adenocarcionoma transcript 1

MEK:

mitogen-activated protein kinase kinase 1

MEN 2A:

multiple endocrine neoplasia type 2A

MGMT:

O-6-methylguanine-DNA methyltransferase

MIR22HG:

MIR22 host gene

miRNA:

micro RNA

MMP-2:

matrix metallopeptidase 2

MRI:

magnetic resonance imaging

MS-HRM:

methylation-sensitive high resolution melting

MTC:

medullary thyroid carcinoma

NIS:

sodium/iodide symporter

P16:

cyclin dependent kinase inhibitor 2A

P53:

tumor protein P53

PPARγ:

peroxisome proliferator activated receptor gamma

PCA3:

prostate cancer antigen 3

PTC:

papillary thyroid carcinoma

PTEN:

phosphatase and tensin homolog

RAI:

radioiodine

RAIR:

radioiodine-refractory

RAIR-DTC:

radioiodine-refractory differentiated thyroid cancer

RARβ2:

retinoic acid receptor beta

RASSF1A:

Ras association domain family member 1

RFLP:

restriction fragment length polymorphism

qRT-PCR:

quantitative real-time polymerase chain reaction; RAS association domain family member 1

RET:

ret. proto-oncogene

SLC5A8:

solute carrier family 5 member 8

TC:

thyroid cancer

TSH:

thyroid-stimulating hormone

TSHR:

thyroid-stimulating hormone receptor.

References

  1. 1.

    Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276–E85.

  2. 2.

    Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid Cancer. Eur Thyroid J. 2019;8(5):227–45.

  3. 3.

    Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M. Radioiodine-refractory thyroid Cancer: molecular basis of Redifferentiation therapies, management, and novel therapies. Cancers. 2019;11(9):1382.

    CAS  PubMed Central  Article  Google Scholar 

  4. 4.

    Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 2013;63(6):373–94.

    PubMed Central  Article  Google Scholar 

  5. 5.

    Larijani B, Mohagheghi MA, Bastanhagh MH, Mosavi-Jarrahi AR, Haghpanah V, Tavangar SM, et al. Primary thyroid malignancies in Tehran, Iran. Med Princ Pract. 2005;14(6):396–400.

  6. 6.

    Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi A, Tavangar S, Malekzadeh R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80–5.

  7. 7.

    Haghpanah V, Shooshtarizadeh P, Heshmat R, Larijani B, Tavangar SM. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol. 2006;14(4):422–5.

    PubMed  Article  Google Scholar 

  8. 8.

    Haghpanah V, Ghaffari SH, Rahimpour P, Abbasi A, Saeedi M, Pak H, et al. Vitamin D receptor gene polymorphisms in patients with thyroid cancer. Gene Ther Mol Biol. 2007;11(2):299–304.

    Google Scholar 

  9. 9.

    Haghpanah V, Khalooghi K, Adabi K, Amiri P, Tavangar SM, Amirzargar A, et al. Associations between HLA-C alleles and papillary thyroid carcinoma. Cancer Biomarkers. 2009;5(1):19–22.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Omidfar K, Moinfar Z, Sohi AN, Tavangar SM, Haghpanah V, Heshmat R, et al. Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Investig. 2009;38(2):165–80.

    CAS  Article  Google Scholar 

  11. 11.

    Tabriz HM, Adabi K, Lashkari A, Heshmat R, Haghpanah V, Larijani B, et al. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Prac. 2009;205(2):83–7.

    Article  Google Scholar 

  12. 12.

    Mohammadi-Asl J, Larijani B, Khorgami Z, Tavangar SM, Haghpanah V, Mehdipour P. Prevalence of BRAFV600E mutation in Iranian patients with papillary thyroid carcinoma: a single-center study. J Appl Sci. 2009;9(19):3593–7. https://doi.org/10.3923/jas.2009.3593.3597.

    Article  Google Scholar 

  13. 13.

    Amoli MM, Yazdani N, Amiri P, Sayahzadeh F, Haghpanah V, Tavangar SM, et al. HLA-DR association in papillary thyroid carcinoma. Dis Markers. 2010;28(1):49–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Alvandi E, Akrami SM, Chiani M, Hedayati M, Nayer BN, Tehrani MRM, et al. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the iranian population. Thyroid. 2011;21(4):373–82. https://doi.org/10.1089/thy.2010.0267.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Irani S, Rashidian A, Yousefi-Nooraie R, Soltani A. Evaluating clinical practice guidelines developed for the management of thyroid nodules and thyroid cancers and assessing the reliability and validity of the AGREE instrument. J Eval Clin Pract. 2011;17(4):729–36. https://doi.org/10.1111/j.1365-2753.2010.01561.x.

    PubMed  Article  Google Scholar 

  16. 16.

    Mohammadi-asl J, Larijani B, Khorgami Z, Tavangar SM, Haghpanah V, Kheirollahi M, et al. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma. Med Oncol. 2011;28(4):1123–8.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med. 2011;36(4):277–82.

    PubMed  Article  Google Scholar 

  18. 18.

    Malehmir M, Haghpanah V, Larijani B, Ahmadian S, Alimoghaddam K, Heshmat R, et al. Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012;348(1):260–9.

    PubMed  Google Scholar 

  19. 19.

    Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, et al. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract. 2012;208(2):100–3.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Sanii S, Saffar H, Tabriz HM, Qorbani M, Haghpanah V, Tavangar SM. Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pac J Cancer Prev. 2012;13(5):2175–8.

    PubMed  Article  Google Scholar 

  21. 21.

    Saffar H, Sanii S, Emami B, Heshmat R, Panah VH, Azimi S, et al. Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors. Pathol Res Pract. 2013;209(3):195–9. https://doi.org/10.1016/j.prp.2012.06.011.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Samimi H, Ghadami M, Khashayar P, Soleimani M, Larijani B, Haghpanah V. MicroRNAs networks in thyroid cancers: focus on miRNAs related to the fascin. J Diabetes Metab Disord. 2013;12(1):31.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  23. 23.

    Samimi H, Ghadami M, Khashayar P, Soleimani M, Larijani B, Haghpanah V. Essential genes in thyroid cancers: focus on fascin. J Diabetes Metab Disord. 2013;12(1):32.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  24. 24.

    Masbi MH, Mohammadiasl J, Galehdari H, Ahmadzadeh A, Tabatabaiefar MA, Golchin N, et al. Characterization of wild-type and mutated RET proto-oncogene associated with familial medullary thyroid cancer. Asian Pac J Cancer Prev. 2014;15:2027–33.

    PubMed  Article  Google Scholar 

  25. 25.

    Haghpanah V, Malehmir M, Larijani B, Ahmadian S, Alimoghaddam K, Heshmat R, et al. The beneficial effects of valproic acid in thyroid cancer are mediated through promoting redifferentiation and reducing stemness level: an in vitro study. J Thyroid Res. 2014;2014:1–9.

    Article  CAS  Google Scholar 

  26. 26.

    Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M, et al. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. Tumor Biol. 2016;37(1):1299–308.

    CAS  Article  Google Scholar 

  27. 27.

    Haghpanah V, Fallah P, Naderi M, Tavakoli R, Soleimani M, Larijani B. Cancer stem-like cell behavior in anaplastic thyroid cancer: a challenging dilemma. Life Sci. 2016;146:34–9.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Khatami F, Larijani B, Heshmat R, Keshtkar A, Mohammadamoli M, Teimoori-Toolabi L et al. Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. 2017;12(9):e0184892. https://doi.org/10.1371/journal.pone.0184892.

  29. 29.

    Samimi H, Fallah P, Sohi AN, Tavakoli R, Naderi M, Soleimani M, et al. Precision medicine approach to anaplastic thyroid cancer: advances in targeted drug therapy based on specific signaling pathways. Acta Medica Iranica. 2017:200–8.

  30. 30.

    Yekta RF, Oskouie AA, Tavirani MR, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: a proteomic study. Int J Biol Markers. 2018;33(4):455–62. https://doi.org/10.1177/1724600818787752.

    CAS  Article  Google Scholar 

  31. 31.

    Yekta RF, Tavirani MR, Oskouie AA, Mohajeri-Tehrani MR, Soroush AR, Baghban AA. Serum-based metabolic alterations in patients with papillary thyroid carcinoma unveiled by non-targeted 1H-NMR metabolomics approach. Iran J Basic Med Sci. 2018;21(11):1140–7. https://doi.org/10.22038/ijbms.2018.30375.7323.

    Article  Google Scholar 

  32. 32.

    Khatami F, Larijani B, Heshmat R, Nasiri S, Saffar H, Shafiee G, et al. Promoter methylation of four tumor suppressor genes in human papillary thyroid carcinoma. Iran J Pathol. 2019;14(4):290–9. https://doi.org/10.30699/IJP.2019.94401.1922.

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Khatami F, Teimoori-Toolabi L, Heshmat R, Nasiri S, Saffar H, Mohammadamoli M, et al. Circulating ctDNA methylation quantification of two DNA methyl transferases in papillary thyroid carcinoma. J Cell Biochem. 2019;120(10):17422–37. https://doi.org/10.1002/jcb.29007.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Samimi H, Haghpanah V, Irani S, Arefian E, Sohi AN, Fallah P, et al. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor “BI-847325” on anaplastic thyroid carcinoma. Daru. 2019;27:1–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Abbasifarid E, Sajjadi-Jazi SM, Beheshtian M, Samimi H, Larijani B, Haghpanah V. The role of ATP-binding cassette transporters in the Chemoresistance of anaplastic thyroid Cancer: a systematic review. Endocrinology. 2019;160(8):2015–23.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Samimi H, Haghpanah V, Irani S, Fallah P, Arefian E, Soleimani M. Determination of ATP-competitive inhibitor drug toxicity in anaplastic thyroid Cancer based on cell characteristics and three-dimensional cell culture. Modares Journal of Biotechnology. 2019;10(3):503–9.

    Google Scholar 

  37. 37.

    Mahdiannasser M, Haghpanah V, Damavandi E, Kabuli M, Tavangar SM, Larijani B, et al. Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas. Mol Biol Rep. 2020;47(3):2161–9. https://doi.org/10.1007/s11033-020-05315-8.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Khatami F, Larijani B, Heshmat R, Nasiri S, Haddadi-Aghdam M, Teimoori-Toolabi L, et al. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAFV600E mutation as biomarkers for papillary thyroid carcinoma. J Cell Physiol. 2020;235(10):6954–68. https://doi.org/10.1002/jcp.29591.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Samimi H, Haghpanah V. Gut microbiome and radioiodine-refractory papillary thyroid carcinoma pathophysiology. Trends Endrocrinol Metab. 2020;31:627–30.

    CAS  Article  Google Scholar 

  40. 40.

    Samimi H, Sajjadi-Jazi SM, Seifirad S, Atlasi R, Mahmoodzadeh H, Faghihi MA, et al. Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review. Cancer Cell Int. 2020;20(1):1–15.

    Article  CAS  Google Scholar 

  41. 41.

    Gholizadeh Siahmazgi Z, Irani S, Ghiaseddin A, Fallah P, Haghpanah V. BIOINFORMATIC study on effect of XANTHOHUMOL as bioactive compound of hop in the inhibition of the MAPK/ERK pathway in thyroid cancer. Iranian Journal of Diabetes and Metabolism. 2020;19(4):225–33.

    Google Scholar 

  42. 42.

    Farrokhi Yekta R, Rezaie Tavirani M, Arefi Oskouie A, Mohajeri-Tehrani MR, Soroush AR. The metabolomics and lipidomics window into thyroid cancer research. Biomarkers. 2017;22(7):595–603. https://doi.org/10.1080/1354750X.2016.1256429.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Khatami F, Tavangar SM. Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. J Diabetes Metab Disord. 2018;17(1):19–30. https://doi.org/10.1007/s40200-018-0334-x.

    PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Khatami F, Tavangar SM. Genetic and epigenetic of medullary thyroid cancer. Iran Biomed J. 2018;22(3):142–50. https://doi.org/10.22034/ibj.22.3.142.

    PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Khatami F, Tavangar SM. A review of driver genetic alterations in thyroid cancers. Iran J Pathol. 2018;13(2):125–35. https://doi.org/10.30699/ijp.13.2.125.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Khatami F, Tavangar SM. Liquid biopsy in thyroid cancer: new insight. Int J Hematol Oncol Stem Cell Res. 2018;12(3):234–47.

    Google Scholar 

  47. 47.

    Khatami F, Larijani B, Nasiri S, Tavangar SM. Liquid biopsy as a minimally invasive source of thyroid cancer genetic and epigenetic alterations. Int J Mol Cell Med. 2019;8:19–29. https://doi.org/10.22088//IIJMCM.BUMS.8.2.19.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Khatami F, Larijani B, Nikfar S, Hasanzad M, Fendereski K, Tavangar SM. Personalized treatment options for thyroid cancer: current perspectives. Pharmgenomics Pers Med. 2019;12:235–45. https://doi.org/10.2147/PGPM.S181520.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Khatami F, Payab M, Sarvari M, Gilany K, Larijani B, Arjmand B, et al. Oncometabolites as biomarkers in thyroid cancer: a systematic review. Cancer Manag Res. 2019;11:1829–41. https://doi.org/10.2147/CMAR.S188661.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Homayouni M, Mohammad Arabzadeh SA, Nili F, Razi F, Amoli MM. Evaluation of the presence of Epstein-Barr virus (EBV) in Iranian patients with thyroid papillary carcinoma. Pathol Res Pract. 2017;213(7):854–6. https://doi.org/10.1016/j.prp.2017.01.020.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Larijani B, Aghakhani S, Khajeh-Dini H, Baradar-Jalili R. Clinico-pathological features of thyroid cancer as observed in five referral hospitals in Iran. Acta Oncol. 2003;42(4):334–7.

    PubMed  Article  Google Scholar 

  52. 52.

    Farzadfar F, Peykari N, Larijani B, Rahimzadeh S, Rezaei-Darzi E, Saeedi MS. A comprehensive study on national and sub national trend in thyroid cancer prevalence in the iranian population, 1990–2010. Iranian Journal of Diabetes and Metabolism. 2016;15(2):91–100.

    Google Scholar 

  53. 53.

    Mohammadi E, Aminorroaya A, Fattahi N, Azadnajafabad S, Rezaei N, Farzi Y, et al. Epidemiologic pattern of cancers in Iran; current knowledge and future perspective. J Diabetes Metab Disord. 2020. https://doi.org/10.1007/s40200-020-00654-6.

  54. 54.

    Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Song H-J, Qiu Z-L, Shen C-T, Wei W-J, Luo Q-Y. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. 2015;173(3):399–408.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110(7):1451–6.

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

In Memory of Professor Mohammad Hasan Bastan Hagh.

Prof. Mohammad Hasan Bastan Hagh was the founder of the Thyroid Research Group of Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences and left long-lasting scientific attainments.

May his soul rest in peace and he will be cherished in our memories forever.

The authors would like to thanks Dr. Mahmood Naderi for his helpful suggestions and advice. Also, the authors are grateful to Ms. Rasha Atlasi for literature search.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vahid Haghpanah.

Ethics declarations

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Samimi, H., Shirzad, N., Sajjadi-Jazi, S.M. et al. Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020. J Diabetes Metab Disord (2021). https://doi.org/10.1007/s40200-020-00702-1

Download citation

Keywords

  • Papillary thyroid carcinoma
  • Follicular thyroid carcinoma
  • Medullary thyroid carcinoma
  • Anaplastic thyroid carcinoma
  • Endocrinology and metabolism research institute